Mouse (i.e., Mus) Patents (Class 435/354)
-
Publication number: 20140255990Abstract: The present invention provides isolated polynucleotides that can serve as translation enhancing elements and their use in protein expression reagents and methods.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicant: Arizona Board of RegentsInventors: John Chaput, Bertram Jacobs, Brian Wellensiek, Julia Flores
-
Publication number: 20140250542Abstract: Provided herein are mitochondrial-nuclear exchanged cells and animals comprising mitochondrial DNA (mtDNA) from one subject and nuclear DNA (nDNA) from a different subject. Methods for producing a mitochondrial-nuclear exchanged animal and animals made by the methods are provided. Also provided are methods of screening for agents useful for treating a disease or disorder using mitochondrial-nuclear exchanged animals or cells, tissues or organs thereof.Type: ApplicationFiled: January 27, 2012Publication date: September 4, 2014Applicant: THE UAB RESEARCH FOUNDATIONInventors: Scott Webster Ballinger, Danny R. Welch, Robert Allen Kesterson, Larry W. Johnson
-
Publication number: 20140248665Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: ApplicationFiled: December 19, 2013Publication date: September 4, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Patent number: 8815589Abstract: The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.Type: GrantFiled: May 9, 2012Date of Patent: August 26, 2014Assignee: The J. David Gladstone InstitutesInventors: Yadong Huang, Karen Ring
-
Patent number: 8815598Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.Type: GrantFiled: July 31, 2006Date of Patent: August 26, 2014Assignees: Fuso Pharmaceutical Industries, Ltd.Inventors: Masaru Okabe, Masahito Ikawa
-
Publication number: 20140237631Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.Type: ApplicationFiled: March 31, 2014Publication date: August 21, 2014Applicants: KIMRON VETERINARY INSTITUTE, INSTITUT PASTEURInventors: Despres Philippe, Vincent Deubel, Jean-Louis Guenet, Marie-Therese Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasseli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
-
Patent number: 8809051Abstract: The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and V?) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.Type: GrantFiled: August 20, 2007Date of Patent: August 19, 2014Assignee: Amgen Fremont Inc.Inventors: Aya Jakobovits, Raju Kucherlapati, Susan Klapholz, Michael J Mendez, Larry Green
-
Publication number: 20140228301Abstract: In one aspect, the disclosure relates to compositions comprising alpha-1-antitrypsin (AAT) and the production thereof. In some embodiments, the AAT is recombinantly produced. The disclosure also relates to methods of administering compositions comprising alpha-1-antitrypsin (AAT).Type: ApplicationFiled: December 19, 2012Publication date: August 14, 2014Inventors: Harry M. Meade, Paul R. Bourdon
-
Publication number: 20140221734Abstract: Genetically modified somatic cells of a non-human animal are provided that are engineered to contain a self-excisable, recombinase expression cassette comprising a site-specific recombinase gene operably linked to an ES cell-specific promoter. Compositions and methods for producing a genetically modified, cloned non-human animal that is free of a selective marker gene and a recombinase gene are provided, wherein a targeting construct comprising a self-excisable recombinase gene operably linked to an ES cell-specific promoter is introduced into differentiated somatic cells. The genetically modified genome of the somatic cells is transferred into an enucleated host oocyte. The artificially created zygote is then cultured in vitro until the blastocyst embryonic stage and subsequently implanted into a uterus of a surrogate mother to form a genetically modified, cloned non-human animal free of selective marker and recombinase genes.Type: ApplicationFiled: November 26, 2013Publication date: August 7, 2014Inventors: Guochun Gong, Ka-Man Venus Lai, David M. Valenzuela
-
Publication number: 20140220555Abstract: Techniques for generating microtissues, including a micro-fabricated platform including at least one micro-well including a plurality of micro-cantilevers coupled thereto and surrounded by a plurality of ridges, each micro-cantilever including a cap at a terminal end thereof. The platform can be immersed in a suspension of cells. The suspension of cells can be driven into at least one micro-well, and the ridges can be de-wetted to remove excess suspension and isolate the suspension of cells in each micro-well. The cells can be driven in the suspension of each micro-well toward a top surface of the suspension, which can be polymerized to form a matrix. The cells can be cultivated to spontaneously compact the matrix such that the micro-cantilevers anchor and constrain the contracting matrix to form a band of microtissue that spans across the micro-cantilevers.Type: ApplicationFiled: April 8, 2014Publication date: August 7, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Christopher S. Chen, Ken Margulies, Thomas Boudou, Wesley Legant, Michael T. Yang
-
Publication number: 20140220634Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: ApplicationFiled: February 6, 2013Publication date: August 7, 2014Applicant: Janssen Biotech, Inc.Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
-
Publication number: 20140213511Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
-
Publication number: 20140208457Abstract: The present invention is concerned with nuclease fusion proteins and various uses thereof. Specifically, it relates to a polynucleotide encoding a polypeptide comprising (i) a first module comprising at least a first DNA binding domain derived from a homing endonuclease, (ii) a linker, and (iii) a second module comprising at least a second DNA binding domain and a cleavage domain derived from a restriction endonuclease, wherein said polypeptide functionally interacts only with DNA comprising a DNA recognition site for the first DNA binding domain and a DNA recognition site for the second DNA binding domain, and wherein said cleavage domain cleaves DNA within a specific DNA cleavage site upon binding of the polypeptide. Further contemplated are a vector and a non-human transgenic organism comprising said polynucleotide as well as a polypeptide encoded by the polynucleotide of the invention.Type: ApplicationFiled: June 8, 2012Publication date: July 24, 2014Applicant: BASF PLANT SCIENCE COMPANY GMBHInventors: Ines Fonfara, Wolfgang Wende, Alfred Pingoud
-
Publication number: 20140206599Abstract: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.Type: ApplicationFiled: March 26, 2014Publication date: July 24, 2014Applicant: Janssen Biotech, Inc.Inventors: Michael Baumann, Gaby Tresch, Steven Jacobs, Karyn O'Neil
-
Patent number: 8785717Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.Type: GrantFiled: June 8, 2005Date of Patent: July 22, 2014Assignee: University of LeicesterInventors: Teizo Fujita, Hans-Wilhelm Schwaeble, Cordula Margaret Stover
-
Publication number: 20140199700Abstract: An object of the present invention is to provide a method of producing intestinal cells by use of pluripotent stem cells as a starting material. According to the present invention, provided is a method of producing intestinal cells, comprising the steps of: (A) inducing differentiation of pluripotent stem cells into definitive endoderm cells; and (B) culturing the definitive endoderm cells in the presence of (2?Z,3?E)-6-bromoindirubin-3?-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) to thereby induce differentiation of the definitive endoderm cells into intestinal cells.Type: ApplicationFiled: October 31, 2011Publication date: July 17, 2014Applicant: LSIP, LLCInventors: Shoen Kume, Soichiro Ogaki, Nobuaki Shiraki, Kazuhiko Kume
-
Patent number: 8778308Abstract: The disclosed invention relates to the observation that nestin expression is a marker for endothelial cell proliferation. Nestin expression is particularly useful as a marker for angiogenesis, particularly for tumor-related angiogenesis. Specifically, nestin serves as an excellent endothelium marker for brain tumors such as gliomas, hemangioblastomas, Schwannomas, medulloblastomas, and meningiomas. Accordingly, the disclosed invention relates to the use of this marker as a basis to model angiogenic activity.Type: GrantFiled: October 28, 2004Date of Patent: July 15, 2014Inventors: Yasuyuki Amoh, Lingna Li, Meng Yang, Ping Jiang
-
Publication number: 20140193856Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.Type: ApplicationFiled: December 20, 2013Publication date: July 10, 2014Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice, Peter Michael Waterhouse
-
Patent number: 8772031Abstract: Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.Type: GrantFiled: May 9, 2013Date of Patent: July 8, 2014Assignee: Korea University Research and Business FoundationInventors: Seungkwon You, Jai-Hee Moon, Jun Sung Kim, Byung Sun Yoon, Jung Han Lee, Eun Kyoung Jun, June Seok Heo
-
Publication number: 20140189895Abstract: The present invention provides a method of artificially repressing gene expression, which is simpler to design than conventional methods (the RNAi, ribozyme and antisense methods) and which allows for easier confirmation of the effect. A method of inhibiting the translation reaction of a target gene, comprising cutting out a part of the poly(A) tail and/or 3?-terminal sequence of the target mRNA is provided.Type: ApplicationFiled: July 17, 2012Publication date: July 3, 2014Applicants: YOSHINDO INC., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGYInventors: Tadashi Wada, Kei Takeda, Hiroshi Handa
-
Publication number: 20140186380Abstract: Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.Type: ApplicationFiled: December 4, 2013Publication date: July 3, 2014Applicant: OncoMed Pharmaceuticals Inc.Inventors: Austin L. GURNEY, Fumiko Takada Axelrod
-
Publication number: 20140189900Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: David Frendewey, David Jonathan Heslin, Ka-Man Venus Lai, David M. Valenzuela
-
Publication number: 20140178985Abstract: The invention relates generally to beta (1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof. In addition, the invention relates to methods for synthesizing oligosaccharides using the beta (1,4)-galactosyltransferase I mutants and to using the beta (1,4)-galactosyltransferase I mutants to conjugate agents, such as therapeutic agents or diagnostic agents, to acceptor molecules.Type: ApplicationFiled: July 16, 2013Publication date: June 26, 2014Inventors: Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman
-
Patent number: 8759105Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: GrantFiled: June 1, 2007Date of Patent: June 24, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aris N. Economides, Andrew J. Murphy, David M. Valenzuela, David Frendewey, George D. Yancopoulos
-
Publication number: 20140171493Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: January 23, 2014Publication date: June 19, 2014Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20140170746Abstract: Provided is a method of dedifferentiating somatic cells using embryonic stem cell-derived microvesicles. Particularly, a method of preparing induced pluripotent stem cells by treating a composition including embryonic stem cell-derived microvesicles to the somatic cells. According to the method of preparing induced pluripotent stem cells, the dedifferentiation of the somatic cells may be efficiently performed without side effects using the embryonic stem cell-derived microvesicles, and moreover, the method is expected to be very useful in developing a cell therapy product having immunocompatibilities by individuals.Type: ApplicationFiled: April 19, 2012Publication date: June 19, 2014Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Jae-Sung Park, Yong Song Gho, Yoon Keun Kim, Jun Ho Kim, Su Chul Jang, Namwoo Yi, Dayeong Jeong, Eun-Jeong Choi
-
Patent number: 8753887Abstract: The present invention relates to the use of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.Type: GrantFiled: September 29, 2006Date of Patent: June 17, 2014Assignee: Centre National de la Recherche ScientifiqueInventors: Marcel Mechali, Jean-Marc Lemaitre
-
Publication number: 20140162281Abstract: Provided are compositions, kits, and methods for separating cells including complexes of at least one type of linker capable of binding to an antibody or antigen binding fragment and a solid phase.Type: ApplicationFiled: April 23, 2013Publication date: June 12, 2014Applicant: Samsung Electronics Co., Ltd.Inventors: Kyung-yeon HAN, Yeon-jeong KIM, Jong-myeon PARK, Chang-eun YOO
-
Publication number: 20140162296Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.Type: ApplicationFiled: March 14, 2013Publication date: June 12, 2014Inventors: Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
-
Publication number: 20140162331Abstract: Disclosed are an amphipathic peptide-lipase conjugate with enhanced lipase activity, a polynucleotide coding for the conjugate, an expression vector carrying the polynucleotide, a transformant anchoring the expression vector therein, a method for preparing the conjugate, a lipolysis method using the conjugate, and a method for producing biodiesel using the lipase.Type: ApplicationFiled: August 10, 2012Publication date: June 12, 2014Inventors: Sun-Chang Kim, Bong Hyun Sung, Kyung Seok Yang, Jun Hyoung Lee, Ki Jung Lim, Myung Keun Park
-
Patent number: 8748179Abstract: A main object of the present invention is to provide a technique to produce iPS cells with less burden on the patient and with high establishment efficiency. iPS cells can be efficiently produced with significantly improved establishment efficiency by selecting cells derived from oral mucosa and introducing, into the cells, reprogramming factors capable of inducing the cells into pluripotent stem cells.Type: GrantFiled: June 23, 2010Date of Patent: June 10, 2014Assignee: Osaka UniversityInventors: Hiroshi Egusa, Hirofumi Yatani, Hiroki Kayashima
-
Patent number: 8748175Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: GrantFiled: November 2, 2009Date of Patent: June 10, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
-
Patent number: 8748176Abstract: Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice.Type: GrantFiled: February 9, 2012Date of Patent: June 10, 2014Assignee: The Regents of the University of CaliforniaInventors: Edwin S. Monuki, Momoko Watanabe
-
Publication number: 20140155325Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 20, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
-
Publication number: 20140155326Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 21, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
-
Publication number: 20140147422Abstract: A method of deriving isolated stem cells including: implanting a matrix in a wound site of a living organism; allowing cells to infiltrate the matrix; removing the matrix containing the infiltrated cells from the wound site; and removing the infiltrated cells from the matrix to provide isolated stem cells. Stem cells produced by this process, stem cells with certain characteristics, and methods for treating wounds using these stem cells are provided.Type: ApplicationFiled: February 3, 2014Publication date: May 29, 2014Applicant: Embro CorporationInventors: Vance D. Fiegel, David R. Knighton
-
Publication number: 20140141444Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
-
Publication number: 20140140965Abstract: The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Applicant: The Schepens Eye Research InstituteInventors: Michael J. Young, Budd A. Tucker, Petr Y. Baranov
-
Publication number: 20140141445Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
-
Patent number: 8728808Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.Type: GrantFiled: March 27, 2012Date of Patent: May 20, 2014Assignee: Intrexon CorporationInventors: Tarlochan Singh Dhadialla, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, Jr., Mohan Philip
-
Publication number: 20140134722Abstract: The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided.Type: ApplicationFiled: June 17, 2010Publication date: May 15, 2014Inventor: Alexey Ryazanov
-
Publication number: 20140134740Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.Type: ApplicationFiled: October 28, 2013Publication date: May 15, 2014Applicant: Sangamo BioSciences, Inc.Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
-
Patent number: 8722405Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, for culturing stem cells in vitro in an undifferentiated state. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or laminin-5 (laminin-322), or their functional domains, the embryonic stem cells proliferated and maintained their pluripotency.Type: GrantFiled: January 4, 2008Date of Patent: May 13, 2014Inventors: Karl Tryggvason, Anna Domogatskaya, Sergey Rodin
-
Patent number: 8722618Abstract: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.Type: GrantFiled: April 27, 2012Date of Patent: May 13, 2014Assignee: Janssen Biotech, Inc.Inventors: Steven Jacobs, Karyn O'Neil, Michael Baumann, Gaby Sennhauser
-
Publication number: 20140130193Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.Type: ApplicationFiled: December 19, 2013Publication date: May 8, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
-
Publication number: 20140120099Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.Type: ApplicationFiled: September 24, 2013Publication date: May 1, 2014Applicants: UCL Business PLC, Ludwig Institute for Cancer ResearchInventors: Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout
-
Publication number: 20140120091Abstract: The present invention provides improved fusion proteins for therapy of autoimmune and cardiovascular disease.Type: ApplicationFiled: October 31, 2013Publication date: May 1, 2014Inventors: Jeffrey A LEDBETTER, Martha LEDBETTER, Vince MONTES, Alan CHAIT, Sonya SLATER
-
Publication number: 20140120154Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: ApplicationFiled: October 26, 2012Publication date: May 1, 2014Inventor: Claresa Levetan
-
Publication number: 20140113957Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.Type: ApplicationFiled: June 21, 2012Publication date: April 24, 2014Inventors: Brian Bettencourt, Kevin Fitzgerald, Stuart Milstein, Martin Maier, Klaus Charisse, Rajeev Kallanthottathil, Satyanarayana Kuchimanchi, Muthiah Manoharan, Tuyen Nguyen
-
Publication number: 20140109244Abstract: In one aspect, the invention provides a transgenic non-human animal model havings germ cells and somatic cells containing an endogenous MMTV-SV40-Spy1A gene sequence introduced into said animal model, or an ancestor of said animal model at an embryonic stage, wherein said gene sequence comprises a mouse mammary tumor virus gene (MMTV), a functionally disrupted SV40 gene (SV40) and a human Spy1A gene. In another aspect, the present invention provides a transgenic non-human animal model whose germ cells and somatic cells contain an endogenous Spy1A-pTRE-Tight gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage. Preferably, the Spy1A-pTRE-Tight animal model expresses the Spy1A and develop cancer, preferably breast cancer, when administered with tetracycline, preferably doxycycline.Type: ApplicationFiled: August 30, 2013Publication date: April 17, 2014Inventors: Lisa Porter, Bre-Anne Fifield, Dorota Lubanska, Espanta Jalili